Castle Biosciences CSTL Other Accounts Payable and Accrued Liabilities
Other Accounts Payable and Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:OtherAccountsPayableAndAccruedLiabilities.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's other accounts payable and accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's other accounts payable and accrued liabilities?
- Castle Biosciences (CSTL) reported other accounts payable and accrued liabilities of $1.34M in Q1 2026.
- How has Castle Biosciences's other accounts payable and accrued liabilities changed year-over-year?
- Castle Biosciences's other accounts payable and accrued liabilities increased by 14.1% year-over-year, from $1.17M to $1.34M.
- What is the long-term trend for Castle Biosciences's other accounts payable and accrued liabilities?
- Over 3 years (2022 to 2025), Castle Biosciences's other accounts payable and accrued liabilities has grown at a 72.4% compound annual growth rate (CAGR), from $415K to $2.13M.